ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: 07/20/2016

ClinicalTrials.gov ID: NCT02716779

Study Identification

Unique Protocol ID:	ML19301
Brief Title:	Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection
Official Title:	Randomized, Multicentric, Partially Double-Blinded Placebo-Controlled Phase II Study for Examining the Influence of Ribavirin on the Initial Virological Response With Treatment of Peginterferon Alfa-2a (40KD) and Ribavirin With a Six Week Pretreatment-Phase of Ribavirin/Placebo or PEG-Interferon Monotherapy in Treatment Naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection
Secondary IDs:	2006-000935-86 [EudraCT Number]

Study Status

Record Verification:	March 2016
Overall Status:	Completed
Study Start:	April 2007
Primary Completion:	April 2010 [Actual]
Study Completion:	April 2010 [Actual]

Sponsor/Collaborators

Sponsor:	Hoffmann-La Roche
Responsible Party:	Sponsor
Collaborators:	Roche Pharma AG

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? Yes Delayed Posting? No
IND/IDE Protocol?:	No
Review Board:	Approval Status: Approved Approval Number: 172/06 Board Name: Ethikkommission Board Affiliation: Ärztekammer des Saarlandes Phone: +49 681 4003 378 Email: ethikkommission@aeksaar.de
Data Monitoring?:	
Plan to Share Data?:	
Oversight Authorities:	Germany: Federal Institute for Drugs and Medical Devices

Study Description

Brief Summary:	This study examined the influence of ribavirin on the initial virological response in treatment-naïve participants with chronic hepatitis C, genotype 1. Participants were randomized to 1 of 3 treatment groups to receive placebo, ribavirin monotherapy 1000 milligrams (mg) to 1200 mg orally daily depending on body weight or pegylated interferon (PEG-IFN) alfa-2a (Pegasys®) 180 micrograms (mcg) subcutaneously (SC) weekly, for 6 weeks. Following the initial 6 weeks, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin (Copegus®) for 12 weeks. If there was an initial virological response after 12 weeks of combination therapy, treatment could be continued for a further 36 weeks outside of the study.
Detailed Description:	

Conditions

Conditions:	Hepatitis C, Chronic
Keywords:	

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2

Intervention Model:	Parallel Assignment
Number of Arms:	3
Masking:	Double Blind (Subject, Investigator)
Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	68 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Pegylated Interferon (PEG-IFN) alfa-2a Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.	Drug: Pegylated Interferon (PEG-IFN) alfa-2a Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Other Names: • Pegasys® Drug: Ribavirin Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Other Names: • Copegus®
Placebo Comparator: Placebo Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.	Drug: Pegylated Interferon (PEG-IFN) alfa-2a Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Other Names: • Pegasys® Drug: Placebo Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Drug: Ribavirin Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight

Arms	Assigned Interventions
	greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Other Names: • Copegus®
Experimental: Ribavirin Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.	Drug: Pegylated Interferon (PEG-IFN) alfa-2a Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Other Names: • Pegasys® Drug: Ribavirin Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Other Names: • Copegus®

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 18 Years

Maximum Age: 70 Years

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- Caucasians, male or female aged between 18 and 70 years
- Indication: serological proof of a chronic hepatitis C infection with positive result of anti-Hepatitis C virus (HCV) test and detectable HCV- Ribo Nucleic Acid (RNA) in serum
- Proven HCV genotype 1 by means of the reverse hybridization assays
- Proven histological infection activity within the liver with or without proven compensated cirrhosis within the last 24 months prior to start of the study (Child-Pugh degree A)

- Participants without previous anti-HCV therapy

Exclusion Criteria:

- Known hypersensitivity to interferon or ribavirin or any of the other component parts
- Pregnant or nursing women, women with child bearing potential and without using a high effective method of contraception. The urine and serum pregnancy test at visit 0 in fertile participants or cohabitants of participants must show a negative result
- Male partners of pregnant women
- Infection with HCV genotype 2, 3, 4, 5, or 6
- Pretreatment with interferon and/or ribavirin
- Immunocompromised participants
- Treatment of systemic anti-neoplastic or immunomodulatoric medication (including supraphysiological doses of steroids or radiation therapy) within the last 6 months prior to the start of treatment and during the complete time interval of study treatment
- Chronic hepatitis due to hepatitis C virus (e.g. haemochromatosis, autoimmunohepatitis, metabolic or alcohol-related liver disease)
- Decompensated liver cirrhosis or liver disease Child-Pugh degree B or C or condition after decompensation
- Signs of a hepatocellular carcinoma within 2 months prior to randomization in case of a cirrhosis or a transition to cirrhosis
- Ascites or esophagus varices with bleedings as documented in anamnesis
- Any medical condition that questions in the opinion of the investigator the participant's enrollment and participation in the trial
- Hemoglobin <13 grams/deciliter (g/dl) in females and <14 g/dl in males in screening phase
- Patients with an increased anemia risk (e.g. thalassemia, spherocytosis, etc.) or patients which would be at a particular medical risk in case of an anemia
- Diagnosed neutropenia <1.500/microliter (mcl) or thrombocytopenia <90.000/mcl in screening phase

Contacts/Locations

Study Officials: Stephan Zeuzem, Prof. Dr.
Study Principal Investigator
Roche Pharma AG, 79639 Grenazch Wyhlen, Germany

Locations: Germany
Homburg/ Saar, Germany, 66424

Berlin, Germany, 13353

Hannover, Germany, 30625

Frankfurt Am Main, Germany, 60590

Frankfurt Am Main, Germany, 60594

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Pre-Assignment Details	Enrollment was 68: 1 participant withdrew during the screening phase and 67 participants were randomized.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

	Description
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Monotherapy

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Started	14	26	27
Completed	14	25	26
Not Completed	0	1	1
Adverse Event	0	1	1

Combination Therapy

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Started	14	25	26
Completed	14	23	25
Not Completed	0	2	1
Adverse Event	0	2	1

Baseline Characteristics

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Baseline Measures

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin	Total
Number of Participants	14	26	27	67

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin	Total
Age, Continuous [units: years] Mean (Standard Deviation)	45.8 (14.4)	48.2 (15.4)	50.2 (12.9)	48.5 (14.1)
Gender, Male/Female [units: participants]				
Female	7	18	17	42
Male	7	8	10	25

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action
Measure Description	To investigate possible action mechanisms, three different models were fitted to viruskinetic data and evaluated using related log-likelihood function values. These models were designed assuming individual effects with respect to infectiousness (model 1), virus production (model 2) or degradation of infected cells rate (model 3). The following viruskinetic parameters were fitted in each model: initial viral load, loss rate of infected cells (delta), effectivity of interferon with respect to a pharmacokinetic-pharmacodynamic model. A lower log likelihood function value indicates a lesser fit for the model.
Time Frame	Up to Day 126
Safety Issue?	No

Analysis Population Description

Per Protocol (PP) population: participants with 6 weeks of monotherapy and at least 4 weeks combination therapy as well as three quantitative HCV-RNA measurements (baseline, period 1, period 2), no major protocol violations, no treatment interruption and no dose reduction below 80% of the planned medication within the first 10 therapy weeks.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Total Participant Group	Combined group of PEG IFN alfa-2a, matching placebo and ribavirin arms.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Ribavirin	Total Participant Group
Number of Participants Analyzed	13	23	61
Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action [units: log likelihood function value] Median (95% Confidence Interval)			
Model 1= infectiousness	-27.0 (-34.5 to -14.0)	-21.4 (-24.7 to -15.2)	-22.2 (-26.0 to -19.3)
Model 2= virus production	-28.2 (-35.0 to -14.3)	-23.8 (-27.5 to -21.6)	-23.9 (-27.4 to -21.6)
Model 3= degradation rate	-27.1 (-33.2 to -14.0)	-20.7 (-25.5 to -16.0)	-23.1 (-26.5 to -18.4)

2. Secondary Outcome Measure:

Measure Title	Score in Quality of Life Assessed Using Short Form-36 (SF-36) Health Questionnaire
Measure Description	SF-36 is a psychometric scale to quantify health conditions. This psychometric scale has 8 dimensions of the subjective health status and consists of 36 individual items that have a varying number of related item scores (ranging from “yes/no” up to a 6-point scale). At first the raw scores were determined by summation over all items and weighted accordingly. Afterwards the raw scores were transformed to ranges of 0-100 with 100 being the highest level of health and compared to published reference scales. The following eight dimensions of subjective health conditions were considered: physical functioning index, role physical index, pain, general health perception, vitality, social functioning index, role emotional index and mental health index. The SF36 questionnaire had to be answered by the patients at screening before monotherapy, after monotherapy and at the end of the study (=end of combination therapy).
Time Frame	At screening (Days -56 to -1), at end of monotherapy (Week 6) and at end of combination therapy (Week 18)
Safety Issue?	No

Analysis Population Description

Intent-to-treat (ITT) population includes all randomized participants who received at least one dose of study drug. Here, 'n' is the number of evaluable participants.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

	Description
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	6	11	17
Score in Quality of Life Assessed Using Short Form-36 (SF-36) Health Questionnaire [units: units on a scale] Mean (Standard Deviation)			
Physical functioning index: Screening	95.6 (5.2)	76.5 (20.2)	79.7 (28.7)
Physical functioning index: End of monotherapy	90.8 (9.2)	72.3 (28.1)	68.4 (27.7)
Physical functioning index: End of comb. therapy	67.1 (20.7)	73.0 (14.0)	53.4 (31.5)
Role physical index: Screening	75.0 (41.8)	55.6 (41.0)	62.5 (40.8)
Role physical index: End of monotherapy	66.7 (34.2)	56.8 (43.4)	50.5 (40.5)
Role physical index: End of combination therapy	25.0 (38.7)	40.0 (35.7)	29.7 (40.0)
Pain: Screening	89.3 (17.0)	70.3 (26.8)	70.0 (30.8)
Pain: End of monotherapy	73.2 (23.3)	61.5 (27.4)	66.0 (29.6)
Pain: End of combination therapy	72.3 (32.2)	56.0 (11.8)	60.1 (34.8)
General health perception: Screening	58.6 (12.9)	53.6 (14.5)	62.9 (14.5)
General health perception: End of monotherapy	58.2 (7.6)	59.2 (16.9)	54.3 (18.0)
General health perception: End of comb. therapy	60.0 (14.3)	55.2 (15.0)	47.1 (20.6)
Vitality: Screening	54.2 (9.2)	52.8 (21.5)	50.9 (18.9)
Vitality: End of monotherapy	45.0 (15.2)	44.1 (16.3)	41.8 (20.1)

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Vitality: End of combination therapy	40.8 (14.6)	32.5 (12.1)	39.8 (16.1)
Social functioning index: Screening	75.0 (23.7)	79.2 (24.2)	83.8 (20.6)
Social functioning index: End of monotherapy	72.9 (22.9)	68.2 (24.0)	80.1 (22.6)
Social functioning index: End of comb. therapy	68.8 (23.4)	61.3 (19.9)	56.3 (25.8)
Role emotional index: Screening	55.6 (50.2)	66.7 (50.0)	62.5 (43.7)
Role emotional index: End of monotherapy	55.6 (50.2)	69.7 (45.8)	53.3 (51.6)
Role emotional index: End of combination therapy	33.3 (51.6)	50.0 (42.3)	35.4 (39.4)
Mental health index: Screening	68.5 (9.1)	63.1 (18.1)	64.5 (15.4)
Mental health index: End of monotherapy	61.3 (12.3)	62.8 (14.0)	61.5 (19.7)
Mental health index: End of combination therapy	72.2 (9.0)	61.6 (13.2)	47.7 (23.0)

3. Secondary Outcome Measure:

Measure Title	Percentage of Participants With Treatment Response
Measure Description	HCV-RNA level was measured at each visit by a central laboratory. Treatment response was estimated applying the following definitions of response/non-response: 1) Adequate first phase decline: HCV RNA decline ≥ 0.5 log10 International Units/milliliter (IU/mL) from time 0 to 48 hours of PEG-IFN treatment (PEG-IFN arm: day 0 – day 2; placebo and ribavirin arm: day 42-day 44), 2) Rapid virologic response: HCV RNA < 15 IU/mL (=detection limit) on day 70, 3) Complete early virologic response: HCV RNA < 15 IU/mL on day 126, 4) Partial early virologic response (log decrease): HCV RNA decrease ≥ 2 log10 IU/mL from day 0 to day 126, 5) Partial early virologic response (cut off): HCV RNA <30000 IU/mL on day 126, 6) Non-response: HCV RNA decrease <2 log10 IU/mL from day 0 to day 126, 7) Null-response: HCV RNA decrease <1 log10 IU/mL from day 0 to day 28 and from day 0 to day 70 for PEG-IFN arm and placebo / ribavirin arm, respectively.
Time Frame	Up to Day 126
Safety Issue?	No

Analysis Population Description

All evaluable participants of the Intent-to-Treat (ITT) population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	14	23	25
Percentage of Participants With Treatment Response [units: percentage of participants]			
Adequate first phase decline	79	65	72

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Rapid virologic response	43	30	20
Complete early virologic response	64	48	72
Partial early virologic response (log decrease)	79	78	84
Partial early virologic response (cut off)	79	78	84
Non-response	21	22	16
Null responder	36	26	12

4. Secondary Outcome Measure:

Measure Title	Area Under the Concentration-Time Curve (AUC) of Ribavirin
Measure Description	Evaluation of ribavirin arm after Day 0. Evaluation of placebo and PEG-IFN arms after Day 42.
Time Frame	From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

	Description
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	13	23	25
Area Under the Concentration-Time Curve (AUC) of Ribavirin [units: (microgram/milliliter)*day ([mcg/ml]*d)] Median (95% Confidence Interval)	186.6 (142.3 to 201.4)	179.4 (142.6 to 203.8)	290.1 (257.6 to 370.5)

5. Secondary Outcome Measure:

Measure Title	Maximum Concentration (Cmax) of Ribavirin
Measure Description	Cmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.
Time Frame	From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.

Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	13	23	25
Maximum Concentration (Cmax) of Ribavirin [units: mcg/ml] Median (95% Confidence Interval)	2.95 (2.79 to 3.60)	2.83 (2.34 to 3.26)	3.37 (2.93 to 4.19)

6. Secondary Outcome Measure:

Measure Title	Time to Maximum Concentration (Tmax) of Ribavirin
Measure Description	Tmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.
Time Frame	From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

	Description
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	13	23	25
Time to Maximum Concentration (Tmax) of Ribavirin [units: weeks] Median (95% Confidence Interval)	6.0 (4.0 to 12.0)	8.0 (6.0 to 12.0)	6.4 (6.1 to 8.0)

7. Secondary Outcome Measure:

Measure Title	Area Under the Concentration-Time Curve (AUC) of PEG-IFN
Measure Description	Evaluation of PEG-IFN arm after Day 0. Evaluation of ribavirin and placebo arms after Day 42.
Time Frame	From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	14	22	25

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Area Under the Concentration-Time Curve (AUC) of PEG-IFN [units: (nanogram/milliliter)*day ([ng/ml]*d)] Median (95% Confidence Interval)	2097.9 (1763.5 to 2997.3)	1270.4 (931.8 to 1572.0)	1164.9 (925.2 to 1461.3)

8. Secondary Outcome Measure:

Measure Title	Maximum Concentration (Cmax) of PEG-IFN
Measure Description	Cmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.
Time Frame	From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

	Description
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	14	22	25
Maximum Concentration (Cmax) of PEG-IFN [units: ng/ml] Median (95% Confidence Interval)	28.77 (22.80 to 32.38)	20.36 (16.92 to 25.83)	19.8 (15.80 to 22.30)

9. Secondary Outcome Measure:

Measure Title	Time to Maximum Concentration (Tmax) of PEG-IFN
Measure Description	Tmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.
Time Frame	From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	14	22	25

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Time to Maximum Concentration (Tmax) of PEG-IFN [units: weeks] Median (95% Confidence Interval)	6.3 (6.1 to 8.0)	12.0 (6.0 to 12.0)	6.0 (6.0 to 12.0)

10. Secondary Outcome Measure:

Measure Title	Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT)
Measure Description	
Time Frame	From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

	Description
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	14	23	25
Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT) [units: (Units/liter)*day ([U/L]*d)] Median (95% Confidence Interval)	5078.3 (4358.3 to 6576.5)	7233.5 (5337.3 to 8656.3)	5231.3 (3917.0 to 5852.5)

11. Secondary Outcome Measure:

Measure Title	Maximum Concentration (Cmax) of GPT
Measure Description	Cmax was obtained directly from the concentration-time data.
Time Frame	From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	14	23	25

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Maximum Concentration (Cmax) of GPT [units: U/L] Median (95% Confidence Interval)	68.5 (59.0 to 112.0)	88.0 (67.0 to 123.0)	75.0 (56.0 to 110.0)

12. Secondary Outcome Measure:

Measure Title	Time to Maximum Concentration (Tmax) of GPT
Measure Description	Tmax was obtained directly from the concentration-time data.
Time Frame	From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Safety Issue?	No

Analysis Population Description

All evaluable participants of the ITT population, who were documented for a total of 126 days of the treatment period.

Reporting Groups

	Description
Pegylated Interferon (PEG-IFN) Alfa-2a	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

	Description
Placebo	Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
Ribavirin	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

Measured Values

	Pegylated Interferon (PEG-IFN) Alfa-2a	Placebo	Ribavirin
Number of Participants Analyzed	14	23	25
Time to Maximum Concentration (Tmax) of GPT [units: days] Median (95% Confidence Interval)	2.8 (2.0 to 28.0)	14.0 (10.0 to 42.5)	3.0 (2.0 to 7.0)

Reported Adverse Events

Time Frame	Up to Day 126
Additional Description	[Not specified]

Reporting Groups

	Description
PEG-IFN Alfa-2a, Period 1 Monotherapy	Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks in period 1. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks.
Placebo, Period 1 Monotherapy	Participants with chronic hepatitis C, genotype 1, received placebo PO for 6 weeks in period 1. Placebo: Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
Ribavirin, Period 1 Monotherapy	Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks in period 1. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks.
PEG-IFN Alfa-2a, Period 2 Combination Therapy	In period 2 participants, who received PEG-IFN monotherapy in period 1, received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks.
Placebo, Period 2 Combination Therapy	In period 2 participants, who received placebo in period 1, received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks.

	Description
Ribavirin, Period 2 Combination Therapy	In period 2 participants, who received ribavirin monotherapy in period 1, received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. Pegylated Interferon (PEG-IFN) alfa-2a: Pegylated Interferon (PEG-IFN) alfa-2a (40KD) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks. Ribavirin: Ribavirin, 1000 mg PO (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks.

Serious Adverse Events

	PEG-IFN Alfa-2a, Period 1 Monotherapy	Placebo, Period 1 Monotherapy	Ribavirin, Period 1 Monotherapy	PEG-IFN Alfa-2a, Period 2 Combination Therapy	Placebo, Period 2 Combination Therapy	Ribavirin, Period 2 Combination Therapy
	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)
Total	0/14 (0%)	1/26 (3.85%)	0/27 (0%)	0/14 (0%)	2/25 (8%)	2/26 (7.69%)
Eye disorders						
Retinal haemorrhage [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	1/25 (4%)	0/26 (0%)
Infections and infestations						
Otitis media [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	1/26 (3.85%)
Urinary tract infection [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	1/26 (3.85%)
Psychiatric disorders						
Depression [A] †	0/14 (0%)	1/26 (3.85%)	0/27 (0%)	0/14 (0%)	1/25 (4%)	0/26 (0%)
Surgical and medical procedures						
Psychotherapy [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	1/26 (3.85%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA (12.1)

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	PEG-IFN Alfa-2a, Period 1 Monotherapy	Placebo, Period 1 Monotherapy	Ribavirin, Period 1 Monotherapy	PEG-IFN Alfa-2a, Period 2 Combination Therapy	Placebo, Period 2 Combination Therapy	Ribavirin, Period 2 Combination Therapy
	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)
Total	9/14 (64.29%)	9/26 (34.62%)	12/27 (44.44%)	12/14 (85.71%)	23/25 (92%)	24/26 (92.31%)
Blood and lymphatic system disorders						
Anaemia [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	2/25 (8%)	1/26 (3.85%)
Iron deficiency anaemia [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	0/25 (0%)	0/26 (0%)
Leukopenia [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Neutropenia [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Thrombocytopenia [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	2/26 (7.69%)
Eye disorders						
Keratoconjunctivitis sicca [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Vision blurred [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Gastrointestinal disorders						
Abdominal pain lower [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Abdominal pain upper [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	1/25 (4%)	1/26 (3.85%)
Constipation [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	2/25 (8%)	0/26 (0%)
Diarrhoea [A] †	1/14 (7.14%)	0/26 (0%)	1/27 (3.7%)	0/14 (0%)	5/25 (20%)	1/26 (3.85%)
Dry mouth [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	1/25 (4%)	1/26 (3.85%)
Nausea [A] †	2/14 (14.29%)	2/26 (7.69%)	1/27 (3.7%)	4/14 (28.57%)	8/25 (32%)	5/26 (19.23%)
Toothache [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
General disorders						

	PEG-IFN Alfa-2a, Period 1 Monotherapy	Placebo, Period 1 Monotherapy	Ribavirin, Period 1 Monotherapy	PEG-IFN Alfa-2a, Period 2 Combination Therapy	Placebo, Period 2 Combination Therapy	Ribavirin, Period 2 Combination Therapy
	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)
Asthenia [A] †	0/14 (0%)	0/26 (0%)	2/27 (7.41%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Chills [A] †	2/14 (14.29%)	1/26 (3.85%)	0/27 (0%)	0/14 (0%)	3/25 (12%)	1/26 (3.85%)
Fatigue [A] †	3/14 (21.43%)	1/26 (3.85%)	4/27 (14.81%)	0/14 (0%)	9/25 (36%)	6/26 (23.08%)
Influenza like illness [A] †	3/14 (21.43%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	5/25 (20%)	9/26 (34.62%)
Pyrexia [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	3/25 (12%)	3/26 (11.54%)
Infections and infestations						
Cystitis [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	0/25 (0%)	0/26 (0%)
Ear infection [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	0/25 (0%)	0/26 (0%)
Nasopharyngitis [A] †	0/14 (0%)	2/26 (7.69%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Pharyngitis [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	0/25 (0%)	0/26 (0%)
Metabolism and nutrition disorders						
Decreased appetite [A] †	1/14 (7.14%)	0/26 (0%)	1/27 (3.7%)	0/14 (0%)	4/25 (16%)	3/26 (11.54%)
Musculoskeletal and connective tissue disorders						
Arthralgia [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	5/25 (20%)	2/26 (7.69%)
Back pain [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	3/25 (12%)	2/26 (7.69%)
Bone pain [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Muscle spasms [A] †	0/14 (0%)	2/26 (7.69%)	1/27 (3.7%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Myalgia [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	2/25 (8%)	1/26 (3.85%)
Pain in extremity [A] †	2/14 (14.29%)	0/26 (0%)	1/27 (3.7%)	2/14 (14.29%)	2/25 (8%)	4/26 (15.38%)
Nervous system disorders						
Disturbance in attention [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	1/25 (4%)	2/26 (7.69%)

	PEG-IFN Alfa-2a, Period 1 Monotherapy	Placebo, Period 1 Monotherapy	Ribavirin, Period 1 Monotherapy	PEG-IFN Alfa-2a, Period 2 Combination Therapy	Placebo, Period 2 Combination Therapy	Ribavirin, Period 2 Combination Therapy
	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)	Affected/ At Risk (%)
Dizziness [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	2/25 (8%)	5/26 (19.23%)
Headache [A] †	2/14 (14.29%)	4/26 (15.38%)	4/27 (14.81%)	2/14 (14.29%)	10/25 (40%)	5/26 (19.23%)
Psychiatric disorders						
Depression [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	2/25 (8%)	0/26 (0%)
Initial insomnia [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	0/25 (0%)	0/26 (0%)
Mood swings [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	2/25 (8%)	1/26 (3.85%)
Sleep disorder [A] †	0/14 (0%)	1/26 (3.85%)	2/27 (7.41%)	0/14 (0%)	4/25 (16%)	2/26 (7.69%)
Respiratory, thoracic and mediastinal disorders						
Cough [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	1/25 (4%)	4/26 (15.38%)
Dyspnoea exertional [A] †	1/14 (7.14%)	0/26 (0%)	1/27 (3.7%)	1/14 (7.14%)	1/25 (4%)	0/26 (0%)
Skin and subcutaneous tissue disorders						
Dry skin [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	2/25 (8%)	0/26 (0%)
Night sweats [A] †	1/14 (7.14%)	0/26 (0%)	0/27 (0%)	0/14 (0%)	0/25 (0%)	0/26 (0%)
Pruritus [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	5/25 (20%)	4/26 (15.38%)
Rash [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	2/14 (14.29%)	2/25 (8%)	4/26 (15.38%)
Urticaria [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	0/25 (0%)	0/26 (0%)
Vascular disorders						
Hypertension [A] †	0/14 (0%)	0/26 (0%)	0/27 (0%)	1/14 (7.14%)	0/25 (0%)	1/26 (3.85%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA (12.1)

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.

Results Point of Contact:

Name/Official Title: Medical Communications
Organization: Hoffmann-La Roche
Phone: 800 821-8590
Email: genentech@druginfo.com